Law.com Subscribers SAVE 30%

Call 855-808-4530 or email [email protected] to receive your discount on a new subscription.

The Intellectual Property StrategistKickerFeaturesTopicsCommercial LawLitigationTechnology Media and TelecomSectionsNewsLJN Newsletters

Federal Circuit Finds Claims Directed to DNA Primers and Methods of Use Unpatentable

By Veronica Mullally Munoz
January 31, 2015

The Federal Circuit's decision in Univ. of Utah Research Found. v. Ambry Genetics Corp., 2014-1361, -1366 (Fed. Cir. Dec. 17, 2014) is the latest in the series of Myriad cases dealing with the patentability of genetic material. The U.S. Supreme Court in Association for Molecular Pathology v. Myriad Genetics, Inc., 133 S.Ct. 2107 (2013), held that claims drawn to isolated DNA were patent-ineligible subject matter. Ambry Genetics (Ambry) began offering BRCA1 and BRCA2 diagnostic testing kits following that decision. In July 2013, Myriad Genetics, the University of Utah Research Foundation, the Trustees of the University of Pennsylvania, HSC Research and Development LP, and Endorecherche, Inc. (collectively “Myriad” hereinafter) sought to, inter alia , enjoin Ambry and asserted infringement of six claims (from three patents) that had not previously been considered by the Federal Circuit or the Supreme Court. The Utah District Court denied Myriad's motion for a preliminary injunction and the Federal Circuit panel, Prost, Clevenger and Dyk affirmed. Circuit Judge Dyk delivered the opinion of the court.

The four composition of matter claims on appeal are directed to primers which are short, synthetic, single-stranded DNA molecules that bind complimentary target DNA and enable synthesis of DNA having all or part of the sequence of a BRCA gene in a DNA polymerase chain reaction (PCR). The two method claims on appeal involve comparison of wild-type BRCA gene sequences with the patient's BRCA gene sequence. The lower court held all six claims patent ineligible as claiming naturally occurring DNA sequences and/or abstract ideas.

This premium content is locked for Entertainment Law & Finance subscribers only

  • Stay current on the latest information, rulings, regulations, and trends
  • Includes practical, must-have information on copyrights, royalties, AI, and more
  • Tap into expert guidance from top entertainment lawyers and experts

For enterprise-wide or corporate acess, please contact Customer Service at [email protected] or 877-256-2473

Read These Next
Why So Many Great Lawyers Stink at Business Development and What Law Firms Are Doing About It Image

Why is it that those who are best skilled at advocating for others are ill-equipped at advocating for their own skills and what to do about it?

Bankruptcy Sales: Finding a Diamond In the Rough Image

There is no efficient market for the sale of bankruptcy assets. Inefficient markets yield a transactional drag, potentially dampening the ability of debtors and trustees to maximize value for creditors. This article identifies ways in which investors may more easily discover bankruptcy asset sales.

The DOJ's Corporate Enforcement Policy: One Year Later Image

The DOJ's Criminal Division issued three declinations since the issuance of the revised CEP a year ago. Review of these cases gives insight into DOJ's implementation of the new policy in practice.

A Lawyer's System for Active Reading Image

Active reading comprises many daily tasks lawyers engage in, including highlighting, annotating, note taking, comparing and searching texts. It demands more than flipping or turning pages.

Protecting Innovation in the Cyber World from Patent Trolls Image

With trillions of dollars to keep watch over, the last thing we need is the distraction of costly litigation brought on by patent assertion entities (PAEs or "patent trolls"), companies that don't make any products but instead seek royalties by asserting their patents against those who do make products.